In Italy, the forecast for Peptic Ulcer and GORD medicine sales from 2024 indicates a consistent decline over the next five years. Starting at 12 USD per capita in 2024, the value decreases annually by approximately 5%, reaching 9.8 USD per capita by 2028. This trend follows a substantial decrease from the previous year and averages a -4.2% CAGR over these years.

Future trends to watch include:

Market shifts towards preventative healthcare and lifestyle adjustments, potentially reducing demand.
Pharmaceutical innovations that might alter treatment protocols, influencing sales dynamics.
Economic factors impacting healthcare budgets and patient affordability in Italy.